At the forefront of global pharmaceutical research is the development of "intelligent" medicines which are effective, affordable and safe, for diseases that are poorly treated (for example, cancer, infections, cardiovascular disease and neurodegeneration). The ideal medicine could be taken by a variety of means (pill, injection or inhaler), but should only act on diseased tissue at a 'specific' site in the body. However, the ability to direct a drug to particular desired locations in the body is still a major scientific challenge. Drugs can easily be degraded en route to their target leading to quickly decreasing drug levels. Higher levels of medication do not circumvent this problem due to potentially increased side effects or toxicity. Some drugs can simply not be delivered to their target due to barriers within the body: the ability to reach specific disease sites while leaving healthy cells intact would mean not only better therapeutic outcomes, but better qualities of life for patients and carers. Benefits through better formulation and targeting will be very apparent for those diseases that are increasing in ageing populations, such as cancer, which is predicted to affect (directly or indirectly) 1 in 3 in the European population by 2020. For these and other devastating diseases new therapeutic regimens are urgently needed. Research into Advanced Therapeutics requires not just scientific innovation but also a changed training paradigm for the scientists involved. Many advanced therapeutic formulations are inherently in the 'nano' size range i.e. larger than conventional drugs such as ibuprofen and paracetamol, but smaller than human cells, and thus spanning the traditional domains of chemistry, biology and medicine. Developing the science of these emergent nanomedicines towards clinical products requires a new generation of researchers trained across multiple scientific disciplines. The Centre for Doctoral Training we propose builds on our existing close partnerships with leading industry and academic institutions world-wide to offer training in the diverse and challenging disciplines underlying pharmaceutical science. The proposed Centre will combine expertise in analytical and medicinal chemistry, with materials science, engineering, biology and industrial pharmaceutics, to equip researchers with the skills they need to develop the next generation of pharmaceutical products. Accordingly, the CDT offers wider benefits to society as researchers trained in the Centre will be attractive to the chemicals, engineering and materials sectors as well as healthcare and medicine. Within the proposed CDT we aim to continue our broad-based training approach, such that researchers will have innovation and entrepreneurial skills, so vital for the developing industry sector. This focus on translational and business skills helped a team from Nottingham in the existing CDT to be winners of the NanoCom business competition in 2012. Ultimately, improvements in the industry and practice of therapeutics combined with enhanced academy / industry pathways to translation offer many future advantages, not just to the science, industry and medical base, but to patients, carers and society as a whole.

Synthesis, the science of making molecules, is central to human wellbeing through its ability to produce new molecules for use as medicines and materials. Every new drug, whether an antibiotic or a cancer treatment, is based on a molecular structure designed and built using the techniques of synthesis. Synthesis is a complex activity, in which bonds between atoms are formed in a carefully choreographed way, and training to a doctoral level is needed to produce scientists with this expertise. Our proposed CDT is tailored towards training the highly creative, technologically skilled scientists essential to the pharmaceutical, biotech, agrochemical and materials sectors, and to many related areas of science which depend on novel molecules. Irrespective of the ingenuity of the synthetic chemist, synthesis is often the limiting step in the development of a new product or the advance of new molecular science. This hurdle has been overcome in some areas by automation (e.g. peptides and DNA), but the operational complexity of a typical synthetic route in, say, medicinal chemistry has hampered the wider use of the technology. Recent developments in the fields of automation, machine learning (ML), virtual reality (VR) and artificial intelligence (AI) now make possible a fundamental change in the way molecules are designed and made, and we propose in this CDT to engineer a revolution in the way that newly trained researchers approach synthetic chemistry, creating a new generation of pioneering innovators. Making use of Bristol's extensive array of automated synthetic equipment, flow reactors, peptide synthesisers, and ML Retrosynthesis Tool, students will learn and appreciate this cutting-edge technology-driven program, its potential and its limitations. Bristol has outstanding facilities, equipment and expertise to deliver this training. At its core will be a state-of-the-art research experience in our world-leading research groups, which will form the majority of the 4-year CDT training period. For the 8 months prior to choosing their project, students with complete a unique, multifaceted Technology & Automation Training Experience (TATE). They will gain hands-on experience in advanced techniques in synthesis, automation, modelling and virtual reality. In conjunction with our Dynamic Laboratory Manual (DLM), the students will also expand their experience and confidence with interactive, virtual versions of essential experimental techniques, using simulations, videos, tutorials and quizzes to allow them to learn from mistakes quickly, effectively and safely before entering the lab. In parallel, they will develop their teamworking, leadership and thinking skills through brainstorming and problemsolving sessions, some of them led by our industrial partners. Brainstorming involves the students generating ideas on outline proposals which they then present to the project leaders in a lively and engaging interactive feedback session, which invariably sees new and student-driven ideas emerge. By allowing students to become fully engaged with the projects and staff, brainstorming ensures that students take ownership of a PhD proposal from the start and develop early on a creative and collaborative atmosphere towards problem solving. TATE also provides a formal assessment mechanism, allow the students to make a fully informed choice of PhD project, and engages them in the use of the key innovative techniques of automation, machine learning and virtual reality that they will build on during their projects. We will integrate into our CDT direct interaction and training from entrepreneurs who themselves have taken scientific ideas from the lab into the market. By combining our expertise in synthesis training with new training platforms in automation, ML/AI/VR and entrepreneurship this new CDT will produce graduates better able to navigate the fast-changing chemical landscape.

This application requests funds to continue and develop the EngD in Formulation Engineering which has been supported by EPSRC since 2001. The EngD was developed in response to the needs of the modern process industries. Classical process engineering is concerned with processing materials, such as petrochemicals, which can be described in thermodynamic terms. However, modern process engineering is increasingly concerned with production of materials whose structure (micro- to nano- scale) and chemistry is complex and a function of the processing it has received. For optimal performance the process must be designed concurrently with the product, as to extract commercial value requires reliable and rapid scale-up. Examples include: foods, pharmaceuticals, paints, catalysts and fuel cell electrodes, structured ceramics, thin films, cosmetics, detergents and agrochemicals. In all of these, material formulation and microstructure controls the physical and chemical properties that are essential to its function. The Centre exploits the fact that the science within these industry sectors is common and built around designing processes to generate microstructure:(i) To optimise molecular delivery: for example, there is commonality between food, personal care and pharmaceuticals; in all of these sectors molecular delivery of actives is critical (in foods, to the stomach and GI tract, to the skin in personal care, throughout the body for the pharmaceutical industry);(ii) To control structure in-process: for example, fuel cell elements and catalysts require a structure which allows efficient passage of critical molecules over wide ranges of temperature and pressure; identical issues are faced in the manufacture of structured ceramics for investment casting;(iii) Using processes with appropriate scale and defined scale-up rules: the need is to create processes which can efficiently manufacture these products with minimal waste and changeover losses.The research issues that affect widely different industry sectors are thus the same: the need is to understand the processing that results in optimal nano- to microstructure and thus optimal effect. Products are either structured solids, soft solids or structured liquids, with properties that are highly process-dependent. To make these products efficiently requires combined understanding of their chemistry, processing and materials science. Research in this area has direct industrial benefits because of the sensitivity of the products to their processes of manufacture, and is of significant value to the UK as demonstrated by our current industry base, which includes a significant number of FMCG (Fast Moving Consumer Goods) companies in which product innovation is especially rapid and consumer focused. The need for, and the added value of, the EngD Centre is thus to bring together different industries and industry sectors to form a coherent underpinning research programme in Formulation Engineering. We have letters of support from 19 companies including (i) large companies who have already shown their support through multiple REs (including Unilever, P+G, Rolls Royce, Imerys, Johnson Matthey, Cadbury and Boots), (ii) companies new to the Centre who have been attracted by our research skills and industry base (including Bayer, Akzo Nobel, BASF, Fonterra (NZ), Bristol Myers Squibb and Pepsico).